K
Kathleen F. Kadow
Researcher at Bristol-Myers Squibb
Publications - 19
Citations - 808
Kathleen F. Kadow is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Mononegavirales & Virus. The author has an hindex of 15, co-authored 19 publications receiving 771 citations.
Papers
More filters
Journal ArticleDOI
Niruriside, a new HIV REV/RRE binding inhibitor from Phyllanthus niruri.
Jingfang Qian-Cutrone,Stella Huang,John J. Trimble,Hui Li,Pin-Fang Lin,M. Alam,Steven E. Klohr,Kathleen F. Kadow +7 more
TL;DR: Niruriside showed specific inhibitory activity against the binding of REV protein to RRE RNA with an IC50 value of 3.3 microM; however, nirur iside did not protect CEM-SS cells from acute HIV infection at concentrations up to 260 microM using an XTT dye reduction assay.
Journal ArticleDOI
Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity.
Gary R. Braslawsky,Kathleen F. Kadow,Jay O. Knipe,Kerry McGoff,Mary A. Edson,Takushi Kaneko,Greenfield Robert S +6 more
TL;DR: It is suggested that internalization of ADM-Hzn immunoconjugates and release of free ADM from the mAb in acidic intracellular compartments were important steps in the mechanism of action ofADM- Hzn immunconjugates.
Journal Article
Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates
Pamela A. Trail,David Willner,Jay O. Knipe,Arris J. Henderson,Shirley J. Lasch,Zoeckler Mary Edson,Mark D. TrailSmith,Terrence W. Doyle,Dalton King,Anna Maria Casazza,Braslawsky Gary R,Joseph P. Brown,Hofstead Sandra J,Greenfield Robert S,Raymond A. Firestone,Kathleen W. Mosure,Kathleen F. Kadow,Michael B. Yang,Karl Erik Hellström,Ingegerd Hellström +19 more
TL;DR: The increased stability of theBR64-S-DOX conjugates resulted in the delivery of more biologically active DOX to tumors with a concomitant increase in potency and efficacy over that which could be achieved with either unconjugated DOX or BR64-SS-DOx conjugate.
Journal ArticleDOI
Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability
Kuo-Long Yu,Ny Sin,Rita L. Civiello,X. Alan Wang,Keith D. Combrink,H. Belgin Gulgeze,Brian Lee Venables,J. J. Kim Wright,Richard A. Dalterio,Lisa Zadjura,Anthony M. Marino,Sandra A. Dando,Celia D’Arienzo,Kathleen F. Kadow,Christopher Cianci,Zhufang Li,Junius Clarke,Eugene V. Genovesi,Ivette Medina,Lucinda Lamb,Richard J. Colonno,Zheng Yang,Mark Krystal,Nicholas A. Meanwell +23 more
TL;DR: A series of benzimidazole-based inhibitors of respiratory syncytial virus (RSV) fusion were optimized for antiviral potency, membrane permeability and metabolic stability in human liver microsomes.
Journal ArticleDOI
Fundamental structure-activity relationships associated with a new structural class of respiratory syncytial virus inhibitor.
Kuo Long Yu,Yi Zhang,Rita L. Civiello,Kathleen F. Kadow,Christopher Cianci,Mark Krystal,Nicholas A. Meanwell +6 more
TL;DR: The results indicate that the topology of the side chain is important but the terminus element offers considerable latitude to modulate physical properties.